Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRO 542

Drug Profile

PRO 542

Alternative Names: CD4 IgG2

Latest Information Update: 21 Feb 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Columbia University
  • Class Antivirals; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins
  • Mechanism of Action HIV fusion inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 04 Nov 2003 Data presented at the 41st Annual Meeting of the Infectious Diseases Society of America (IDSA-2003) have been added to adverse events and Viral Infections antimicrobial activity sections
  • 11 Dec 2002 A clinical study has been added to the Viral Infections antimicrobial activity section
  • 25 Oct 2002 Epicyte has been awarded a NIH grant for the large-scale production of hybrid antibodies that block HIV transmission, including PRO 542
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top